Superworth

Pacira BioSciences EV/EBIT PCRX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026
7.6×
8-year median
27.8×
Against its 8-year history
6th
percentile: 0 is its lowest day, 100 its highest
8-year range
4.9× to 447×
Peer median
9.9×

Pacira BioSciences' EV/EBIT is 7.6× as of Oct 23, 2026.

That is below its 8-year median of 27.8×, lower than on 94% of days in the last 8 years.

Over that time it ranged from 4.9× in Jun 2026 to 447× in Sep 2018.

The median for 10 large drugmakers of a similar size is 9.9×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.6×4.9×22.0×
202517.0×9.7×21.0×
202410.2×7.8×26.7×
202326.3×19.5×32.0×
202226.9×24.3×46.0×
202124.3×20.7×99.5×
202077.4×56.2×145×
201982.7×61.3×130×
2018136×133×447×
2017n/m a value too high to mean anything
2016337×182×479×
2015439×352×461×

Against its peers

Companies in Drug Manufacturers - General nearest Pacira BioSciences' size, closest first, today.

CompanyEV/EBIT
PCRXPacira BioSciences7.6×
ANABAnaptysbion/m
PAHCPhibro Animal Health11.7×
ANIPANI Pharmaceuticals10.5×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals12.2×
HRMYHarmony Biosciences6.9×
PBHPrestige Consumer Healthcare14.5×
ABUSArbutus Biopharma4.9×
NRIXNurix Therapeutics7.1×
COLLCollegium Pharmaceutical9.4×
Peer median9.9×

Where Pacira BioSciences ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Pacira BioSciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.